Paradigm Biopharmaceuticals: Completes osteoarthritis treatment in 10 ex-NFL patients
- Paradigm Biopharmaceuticals has completed its osteoarthritis treatment for 10 ex-NFL patients under a U.S. Expanded Access Program
- All patients were given Paradigm’s Zilosul knee osteoarthritis treatment product
- Zilosul contains a compound which is also used to treat inflammation
- Paradigm also expects to receive results from all 10 patients in the third quarter of the 2020 calendar year
- The U.S. Food and Drug Administration (FDA) has also granted Paradigm’s MPS-I treatment Orphan Drug Designation
- Paradigm is up a slight 3.20 per cent on the market and shares are trading for $1.94 each
